GLENN ARCHIBALD: Open Payments
NPI 1316947450 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,857 in 226 payments from 21 companies in 2025. Trend: 2023 $4,502 · 2024 $4,848 · 2025 $4,857
Food & beverage: $4,746Education: $111
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 25 | $677 |
| Otsuka America Pharmaceutical, Inc. | 25 | $575 |
| Alkermes, Inc. | 18 | $478 |
| Teva Pharmaceuticals USA, Inc. | 23 | $459 |
| ABBVIE INC. | 36 | $377 |
| Supernus Pharmaceuticals, Inc. | 19 | $374 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $298 |
| Neuronetics, Inc. | 2 | $257 |
| Corium, LLC | 8 | $174 |
| Janssen Pharmaceuticals, Inc | 4 | $165 |
Products named: FANAPT, REXULTI, ARISTADA, VRAYLAR, Qelbree, AUSTEDO XR, CAPLYTA, NEUROSTAR TMS THERAPY SYSTEM.
Industry payments across AL — which companies pay providers there.
